The combination of stabilized plasmid lipid particles and lipid nanoparticle encapsulated CpG containing oligodeoxynucleotides as a systemic genetic vaccine

DNA vaccines offer unique potential for generating protective and therapeutic immunity against infectious and malignant diseases. Unfortunately, rapid degradation and poor cellular uptake has significantly limited the efficacy of ‘naked’ plasmid DNA vaccines. We have previously described stabilized plasmid lipid particles (SPLP) as effective nonviral gene delivery vehicles for the transfection of tumours at distal sites following intravenous administration. Based on their low toxicity and favourable transfection profile following systemic administration, we investigate SPLP as gene delivery vehicles for the generation of a systemically administered genetic vaccine.

[1]  P. Cullis,et al.  Effects of intravenous and subcutaneous administration on the pharmacokinetics, biodistribution, cellular uptake and immunostimulatory activity of CpG ODN encapsulated in liposomal nanoparticles. , 2007, International immunopharmacology.

[2]  M. Albertini,et al.  Hydrodynamic limb vein delivery of a xenogeneic DNA cancer vaccine effectively induces antitumor immunity. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  P. Cullis,et al.  Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN , 2007, Cancer Immunology, Immunotherapy.

[4]  Shubiao Zhang,et al.  Toxicity of cationic lipids and cationic polymers in gene delivery. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[5]  A. Judge,et al.  Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[6]  D. Weiner,et al.  From Plasmids to Protection: A Review of DNA Vaccines Against Infectious Diseases , 2006, International reviews of immunology.

[7]  J. Heyes,et al.  Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression. , 2005, Biochimica et biophysica acta.

[8]  L. Jeffs,et al.  A Scalable, Extrusion-Free Method for Efficient Liposomal Encapsulation of Plasmid DNA , 2005, Pharmaceutical Research.

[9]  G. Prud’homme.  DNA vaccination against tumors , 2005, The journal of gene medicine.

[10]  Jiaqiang Ren,et al.  Co-administration of a DNA vaccine encoding the prostate specific membrane antigen and CpG oligodeoxynucleotides suppresses tumor growth , 2004, Journal of Translational Medicine.

[11]  S. Kawakami,et al.  Enhancement of immune responses by DNA vaccination through targeted gene delivery using mannosylated cationic liposome formulations following intravenous administration in mice. , 2004, Biochemical and biophysical research communications.

[12]  H. Yamagishi,et al.  Intravascular naked DNA vaccine encoding glycoprotein B induces protective humoral and cellular immunity against herpes simplex virus type 1 infection in mice , 2003, Gene Therapy.

[13]  K. Hamajima,et al.  Adjuvant effect of multi-CpG motifs on an HIV-1 DNA vaccine. , 2002, Vaccine.

[14]  W-Q Huang,et al.  The humoral immune responses elicited in mice by inoculations with a recombinant protein or DNA based on the circumsporozoite-protein gene of Plasmodium falciparum , 2002, Annals of tropical medicine and parasitology.

[15]  M. Hope,et al.  Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles. , 2001, The Journal of pharmacology and experimental therapeutics.

[16]  P. Cullis,et al.  Spontaneous entrapment of polynucleotides upon electrostatic interaction with ethanol-destabilized cationic liposomes. , 2001, Biophysical journal.

[17]  P. Cullis,et al.  Stabilized Plasmid–Lipid Particles: Pharmacokinetics and Plasmid Delivery to Distal Tumors following Intravenous Injection , 2000, Journal of drug targeting.

[18]  C. Renner,et al.  Comparison of a Monte Carlo Strategy with a Combined DG/MDSA Method for Structure Determination of Bicyclic Peptides , 1999 .

[19]  Y. Tan,et al.  The inhibitory role of CpG immunostimulatory motifs in cationic lipid vector-mediated transgene expression in vivo. , 1999, Human gene therapy.

[20]  Mario Roederer,et al.  Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients , 1999, Nature Medicine.

[21]  Simon C Watkins,et al.  Effect of immune response on gene transfer to the lung via systemic administration of cationic lipidic vectors. , 1999, American journal of physiology. Lung cellular and molecular physiology.

[22]  R. Purcell,et al.  Route and Method of Delivery of DNA Vaccine Influence Immune Responses in Mice and Non-Human Primates , 1999, Molecular medicine.

[23]  I. Maclachlan,et al.  Cationic lipid-mediated transfection of cells in culture requires mitotic activity , 1999, Gene Therapy.

[24]  R. Germain,et al.  Predominant Role for Directly Transfected Dendritic Cells in Antigen Presentation to CD8+ T Cells after Gene Gun Immunization , 1998, The Journal of experimental medicine.

[25]  D. Weiner,et al.  Specific immune induction following DNA-based immunization through in vivo transfection and activation of macrophages/antigen-presenting cells. , 1998, Journal of immunology.

[26]  J. Nordstrom,et al.  Cationic lipids enhance cytokine and cell influx levels in the lung following administration of plasmid: cationic lipid complexes. , 1998, Journal of immunology.

[27]  J. V. D. van der Want,et al.  Lymphatic uptake and biodistribution of liposomes after subcutaneous injection . IV. Fate of liposomes in regional lymph nodes. , 1998, Biochimica et biophysica acta.

[28]  N. Phillips,et al.  Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells. , 1997, Biochimica et biophysica acta.

[29]  G. Storm,et al.  Lymphatic Uptake and Biodistribution of Liposomes After Subcutaneous Injection: III. Influence of Surface Modification with Poly(ethyleneglycol) , 1997, Pharmaceutical Research.

[30]  A. Iwasaki,et al.  The dominant role of bone marrow-derived cells in CTL induction following plasmid DNA immunization at different sites. , 1997, Journal of immunology.

[31]  D. Klinman,et al.  Contribution of CpG motifs to the immunogenicity of DNA vaccines. , 1997, Journal of immunology.

[32]  Simon C Watkins,et al.  DNA–based immunization by in vivo transfection of dendritic cells , 1996, Nature Medicine.

[33]  D. Carson,et al.  Gene vaccination with naked plasmid DNA: mechanism of CTL priming , 1996, The Journal of experimental medicine.

[34]  C. Walker,et al.  Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[35]  M. Yokoyama,et al.  DNA immunization: effects of vehicle and route of administration on the induction of protective antiviral immunity. , 1996, FEMS immunology and medical microbiology.

[36]  G. Splitter,et al.  Interferon-gamma inhibits transgene expression driven by SV40 or CMV promoters but augments expression driven by the mammalian MHC I promoter. , 1995, Human gene therapy.

[37]  M. Hashida,et al.  The Fate of Plasmid DNA After Intravenous Injection in Mice: Involvement of Scavenger Receptors in Its Hepatic Uptake , 1995, Pharmaceutical Research.

[38]  S. Parker,et al.  Cancer gene therapy using plasmid DNA: pharmacokinetic study of DNA following injection in mice. , 1995, Human gene therapy.

[39]  H L Robinson,et al.  DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[40]  J. Ulmer,et al.  Heterologous protection against influenza by injection of DNA encoding a viral protein. , 1993, Science.

[41]  D. Tang,et al.  Genetic immunization is a simple method for eliciting an immune response , 1992, Nature.

[42]  H. Shiku,et al.  [DNA vaccine]. , 2008, Nihon rinsho. Japanese journal of clinical medicine.

[43]  Leaf Huang,et al.  Non-viral vector as vaccine carrier. , 2005, Advances in genetics.

[44]  R. Langer,et al.  Nonviral delivery of cancer genetic vaccines. , 2005, Advances in biochemical engineering/biotechnology.

[45]  I. Maclachlan,et al.  "Diffusible-PEG-Lipid Stabilized Plasmid Lipid Particles" , 2005, Advances in genetics.

[46]  Joshy Jacob,et al.  Genetic tagging shows increased frequency and longevity of antigen-presenting, skin-derived dendritic cells in vivo , 2003, Nature Immunology.

[47]  H. Alpár,et al.  Current status of DNA vaccines and their route of administration. , 2002, Critical reviews in therapeutic drug carrier systems.

[48]  I. Maclachlan,et al.  Stabilized plasmid-lipid particles: a systemic gene therapy vector. , 2002, Methods in enzymology.

[49]  S. Gurunathan,et al.  DNA vaccines: immunology, application, and optimization*. , 2000, Annual review of immunology.

[50]  O. Ludkovski,et al.  Stabilized plasmid-lipid particles for systemic gene therapy. , 2000, Gene therapy.

[51]  G. Nolan,et al.  Improved FACS-Gal: flow cytometric analysis and sorting of viable eukaryotic cells expressing reporter gene constructs. , 1991, Cytometry.

[52]  R. Juliano.  Liposomes and the Reticuloendothelial System: Interactions of Liposomes with Macrophages and Behavior of Liposomes In Vivo , 1982 .